Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective open-labeled phase I trial based on a dose escalating study design
assessing two dose levels of sirolimus when prescribed in combination with metronomic
cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion
cohort once the Maximum Tolerated Dose (MTD) is established.